TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!
One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP presenting our latest product portfolio and innovations to our existing and potential new partners. Check out our short video to get some impressions!
For further information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
TIEFENBACHER PHARMACEUTICALS New market launch: LACOSAMIDE
TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the epilepsy medicine Lacosamide in Australia
We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their income level or nationality. That´s why Tiefenbacher Pharmaceuticals is happy to share that we have successfully prepared the launch of the generic version of Lacosamide for a market entry on day one after patent expiration in Australia.
Lacosamide is used for the treatment of seizures improving the life of patients suffering from epilepsy. The tablets will be marketed in Australia in the strengths 50mg, 100mg, 150mg, and 200mg by our partner, one of the biggest generic pharmaceutical companies in the world. Our product has already been launched in time in several patent-free European markets. A launch in further countries will follow as soon as the patents of the originator product expire. With this early market entry, TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.
We will keep you updated about generic launches and other products in further international markets.
For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu
TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com
TIEFENBACHER PHARMACEUTICALS stands with Ukraine
Peace and freedom for Ukraine: We, a pharmaceutical company in Europe, stand in solidarity with the people in Ukraine
To us at Tiefenbacher Pharmaceuticals, it is unbearable to witness what is happening in Ukraine. We condemn the Russian state´s invasion as a brutal act of war against a neighbouring sovereign country. Our thoughts are with everyone affected by this war. We stand with all Ukrainians and have already donated urgently needed medicine to a hospital in Kyiv and are currently checking further supply options. To support emergency aid for children and families in Ukraine we have also made a significant monetary donation to UNICEF.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
MEET TIEFENBACHER PHARMACEUTICALS DURING DCAT WEEK IN NEW YORK CITY 2022
Meet TIEFENBACHER PHARMACEUTICALS during DCAT week in New York City 2022 from 21-24th march!
Reach out to TIEFENBACHER PHARMACEUTICALS at DCAT in New York City from 21-24th March and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before! Contact us to schedule a meeting via info@aet.eu.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!
We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three main locations in Hamburg (Germany), Hyderabad (India) and Lefkosia (Cyprus).
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide.
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER GROUP enlarges its manufacturing facilities for powerful drug production
Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities in India and Cyprus for powerful drug production
Did you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world?
As fully integrated pharmaceutical company, we offer a competitive supply chain management through our two own manufacturing plants in India and Cyprus. Our facilities are equipped with sophisticated technology from the first manufacturing step throughout to the last packaging step and warehousing. We are flexible to manage small batch as well as high volume productions. While our SPC waiver site in Cyprus is your perfect plant for high volume production made in Europe, our FDA approved site in India is your ideal fit for special technologies and small batch production. Both sites are currently further enlarging their production capacities, equipment, and warehouse storage – to drive efficiency and meet the growing demand of our customers. Our two own manufacturing sites as well as our global network of contract manufacturers allow us to manufacture nearly any kind of formulation and dosage form. No matter if a controlled drug or a special dosage form – our about 60 years experience and our excellent know how in terms of regulatory and quality requirements guarantee the best possible supply chain for you. All our plants are equipped with highly qualified professionals and highest safety standards. This ensures full compliance with Good Manufacturing Practice (GMP). Apart from the most important governmental approvals, our sites are periodically inspected by leading pharmaceutical companies.
For further information about our manufacturing facilities and innovative health care solutions please contact TIEFENBACHER GROUP at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER PHARMACEUTICALS at CPhI 2021 – thanks for visiting us in Milano!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, at CPHI in Milano
With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma eventt CPHI has just come to an end. It was three very successful days for TIEFENBACHER PHARMACEUTICALS presenting our latest product portfolio and innovations at Fiera Milano. After two years of mainly digital work it was a great experience to finally meet our valued customers and partners in person again. Our experts have come home with lots of new inspirations and business ideas and are already looking forward to reconnecting soon. Check out our short video to get an impression of our brand-new booth representing TIEFENBACHER GROUP as a global health pioneer.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER GROUP: New school building in India
Social Responsibility and Community Engagement
At TIEFENBACHER GROUP giving back to society is important to us: New school building in India
As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society – especially in the countries in which we operate.
That’s why we are happy to share that we have build up a new school next to our own R&D and manufacturing facilities in Hyderabad, India, to improve the education and health of the children in our neighborhood. The “Anganwadi school” follows international standards of Kindergarten and has already started to educate 25 children from Alinagar village in the age of 3-8. With this initiative we give underprivileged children from poor families the chance to have a better future through better education and nutrition.
Anganwadi is a type of rural child care center in India. They were started by the Indian government in 1975 as part of the Integrated Child Development Services program to improve the nutrition and health status of children and to reduce morbidity, mortality and school dropout – laying the foundation for holistic development of children.
For TIEFENBACHER GROUP it is a rewarding experience to give back to the community. Our caring culture is fundamental to achieve our purpose to make everyday life significantly better for people around the world. We will continue promoting education and health in various community engagement projects that are in line with our values and beliefs.
For further information about our corporate responsibility or our worldwide health care solutions please contact TIEFENBACHER GROUP by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER PHARMACEUTICALS at CPhI in Milan 2021
Reach out to TIEFENBACHER PHARMACEUTICALS at CPHI in Milan 2021 and discover our latest innovations to make pharmaceuticals more affordable, more available, and better than before.
“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to be back on the world´s leading pharma industry event CPhI in Milan to meet our valued customers and partners finally in person again.
Explore our brand-new booth representing Tiefenbacher Group as a global health pioneer and discover our latest product portfolio and innovations!! Connect with our experts to discuss new business opportunities and ideas for improving the life of millions of patients worldwide!
CPhI 2021 will take place on November 9-11th at Fiera Milano, Italy. We’ll be happy to meet you at our stand 3H11. The arrangement of prescheduled meetings is highly appreciated due to Covid-19 and limited booth time and space. Please contact our team to request a meeting or send a meeting request to cphi@aet.eu.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms.
TIEFENBACHER PHARMACEUTICALS New market launch: antihistamine Bilastine
We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why Tiefenbacher Pharmaceuticals is excited to share that the launch of the first generic version of Bilastine (20 mg tablets) in Spain was a total success.
Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms, such as hay fever and urticaria. The second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis (like sneezing and red, streaming eyes) as well as urticaria caused symptoms (like itchy skin).
With this generic market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment. Following our global market entry approach, a launch in several further international countries is already in preparation.
We will keep you updated about launches of this and other products in further international markets.
For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu
TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – Pioneering Healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com
